TKNO Alpha Teknova, Inc.
Q3 2025 10-Q
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR Alpha Teknova, Inc. (TKNO) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • No newly added risk factors disclosed compared to prior 10-K
- • Operating loss reduced to $4.3M Q3 2025 from $7.6M Q3 2024 reflecting modest expense increase but ongoing unprofitability risk
Quarterly Financial SummaryXBRL
Revenue
$10M
▲ +9.2% YoY▲ +1.6% QoQ
Net Income
-$4M
▲ +43.3% YoY▼ -20.1% QoQ
Gross Margin
30.7%
▲ +2973bp YoY▼ -806bp QoQ
Operating Margin
-38.4%
▲ +3919bp YoY▼ -551bp QoQ
Net Margin
-41.0%
▲ +3800bp YoY▼ -629bp QoQ
ROE
-5.9%
Total Assets
$108M
EPS (Diluted)
$-0.08
▲ +42.9% YoY▼ -33.3% QoQ
Operating Cash Flow
-$2M
▲ +3.8% YoY▲ +5.8% QoQ
Source: XBRL data from Alpha Teknova, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Alpha Teknova, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.